After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
Losing: A film that does not recover the investment but loses less than 50% of it Flop: Film that loses 50% or more of its investment * denotes that the film is still running in theatres Explore how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results